Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06267924 · ClinicalTrials.gov registry record · NA
SENSE-VM: Safety and Effectiveness of a Novel Medical Device for Symptom Ease in Vestibular Migraines
A NA study, sponsored by Otolith Labs.
- Completed
- Registry status
- NA
- Development phase
- 322
- Enrollment target
NCT06267924 is a NA study that has completed, run by Otolith Labs. The registered enrollment target is 322 participants.
The verdict
NCT06267924, a NA study, has completed, sponsored by Otolith Labs.
- COMPLETED
- Registry status
- NA
- Development phase
- 322 participants
- Enrollment target
Study Summary
The goal of this virtual clinical trial is to compare the effectiveness of two study devices in providing temporary relief to adults aged 18-75 who suffer from symptoms of chronic Vestibular Migraines (VM), also known as Migraine Associated Vertigo. Participants will be: * Enrolled up to 50 days; enrollment, 14 days in Baseline Phase (no device), 7 days in Transition Phase, 28 days in Treatment Phase (study device) * Randomized and stratified into groups based on the referring clinic to be assigned one study device * Asked to use the study device as instructed by the study coordinator * Asked to submit daily diaries reporting their symptoms and use of device, and to participate in tele-health visits with study coordinators * Asked to provide their vertigo diagnosis from their physician * Compensated for their participation Researchers will compare the randomized groups to determine which group responds better to which device.
Interventions
- DEVICE Otoband Experimental
- DEVICE Otoband Sham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2024-03-06 |
| Est. Completion | 2025-01-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06267924
The ClinicalTrials.gov registry entry for NCT06267924 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 322 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otolith Labs, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Otoband Experimental is the first listed.
NCT06267924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06267924 about?
NCT06267924 is a clinical study titled "SENSE-VM: Safety and Effectiveness of a Novel Medical Device for Symptom Ease in Vestibular Migraines". The goal of this virtual clinical trial is to compare the effectiveness of two study devices in providing temporary relief to adults aged 18-75 who suffer from symptoms of chronic Vestibular Migraines (VM), also known as Migraine Associated Vertigo. Participants will be: * Enrolled up to 50 days; ...
What is the current status of trial NCT06267924?
This trial is currently completed. It is a NA study. The enrollment target is 322 participants. The study started on 2024-03-06. Estimated completion is 2025-01-08.
What interventions are being tested in trial NCT06267924?
The interventions under investigation include: Otoband Experimental (DEVICE), Otoband Sham (DEVICE).
Who is sponsoring clinical trial NCT06267924?
This trial is sponsored by Otolith Labs, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.